跳至主要内容
临床试验/CTRI/2010/091/001453
CTRI/2010/091/001453尚未招募3 期

Evaluation of Efficacy And Safety of IP-020 in the treatment of Attention deficit hyperactivity disorder (ADHD): A randomized, double-blind, placebo-controlled, multi-center study.

Sun Pharmaceutical Industries Ltd.0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male or Female patients aged 6 to 18.
  • 2.Patients diagnosed with ADHD by DSM-IV for ADHD criteria will be enrolled for the study.
  • 3.Patients whose parents and/or guardians provide written informed consent. (Parents and/or guardians signature is mandatory).

排除标准

  • 1.Patients who has concurrent of history of a significant medical or psychiatric illness (schizophrenia, bipolar disorder or autism) that could have interfered with study participation or assessments.
  • 2.Patients who has marked anxiety, tension and agitation.
  • 3.Patients with Cardiovascular disease or problem.
  • 4.Patients with Glaucoma.
  • 5.Patients with a known or suspected history of drug or alcohol abuse or dependence within the previous 6 months.
  • 6.Patients have a history of poor response or intolerance of CNS stimulant viz. amphetamines salts or dextro-amphetamine salts.
  • 7.Patients who are taking Clonidine or other centrally-acting alpha-2-agonists.
  • 8.Patinets who are hypersensitive to Mehylphenidate.
  • 9.Patients with clinically significant abnormal Vital Signs, judged by investigator.

研究者

相似试验